title: MPO density in primary cancer biopsies of ovarian carcinoma enhances the indicative value of IL-17 for chemosensitivity.
abstract: Cancer of the ovary is mostly discovered at a late stage and cannot be removed by surgery alone. Therefore surgery is usually followed by adjuvant chemotherapy. However, few reliable biomarkers exist to predict response to chemotherapy of ovarian cancer. Previously, we could demonstrate that IL-17 density is indicative for chemosensitivity. This study focuses on the predictive value of myeloperoxidase (MPO) concerning response to chemotherapy of ovarian cancer.
  
  
  
  Biopsies of mostly high-grade primary serous ovarian carcinomas and their matched recurrences were stained with MPO after fixation in formalin and embedding in paraffin. For this staining the technique of tissue-microarray was used. Recurrence within 6 months of the completion of platinum-based chemotherapy was defined as chemoresistance as previously publised. Data for MPO could be analyzed in 92 biopsies.
  
  
  
  MPO and IL-17 positive immune cells correlated significantly in biopsies of primary and recurrent carcinomas (r s = 0.41; p = 0.004 and r s = 0.40; p = 0.007, respectively). MPO expression alone did not predict response to chemotherapy, but in multivariate cox regression analysis including age, residual disease, number of chemotherapy cycles, FIGO classification and combined categorized MPO and IL-17 cell densities of primary cancer biopsies, the combination of both immune markers was an independent prognostic factor for recurrence-free survival (p = 0.013, HR = .23, 95CI = 0.07-0.73). There was no chemoresistant patient in the subgroup of MPO + IL-17+, neither in primary nor in recurrent cancer biopsies.
  
  
  
  High MPO positive cell density enhances the indicative value of IL-17 for response to chemotherapy in ovarian carcinoma. Although, these results have to be validated in a larger cohort.
authors.affiliation: Department of Surgery, University Hospital Basel, Spitalstrasse 21, 4031, Basel, Switzerland. Raoul.Droeser@usb.ch.|Institute for Surgical Research and Hospital Management ICFS, Hebelstrasse 20, 4031, Basel, Switzerland. Raoul.Droeser@usb.ch.
authors.forename: Raoul A
authors.initials: RA
authors.lastname: Droeser
authors.affiliation: Department of Surgery, University Hospital Basel, Spitalstrasse 21, 4031, Basel, Switzerland.
authors.forename: Robert
authors.initials: R
authors.lastname: Mechera
authors.affiliation: Department of Surgery, University Hospital Basel, Spitalstrasse 21, 4031, Basel, Switzerland.
authors.forename: Silvio
authors.initials: S
authors.lastname: Däster
authors.affiliation: Department of Surgery, University Hospital Basel, Spitalstrasse 21, 4031, Basel, Switzerland.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Weixler
authors.affiliation: Department of Surgery, University Hospital Basel, Spitalstrasse 21, 4031, Basel, Switzerland.
authors.forename: Marko
authors.initials: M
authors.lastname: Kraljević
authors.affiliation: Department of Surgery, University Hospital Basel, Spitalstrasse 21, 4031, Basel, Switzerland.
authors.forename: Tarik
authors.initials: T
authors.lastname: Delko
authors.affiliation: Department of Gynecology and Obstetrics, Kantonsspital Winterthur, Brauerstrasse 15, 8400, Winterthur, Switzerland.|Department of Gynecology and Obstetrics, University Hospital Basel, Spitalstrasse 21, 4031, Basel, Switzerland.
authors.forename: Uwe
authors.initials: U
authors.lastname: Güth
authors.affiliation: Institute of Pathology, Kantonsspital Baden AG, Im Ergel 1, 5404, Baden, Switzerland.|Institute of Pathology, University Hospital Basel, Schönbeinstrasse 40, 4031, Basel, Switzerland.
authors.forename: Sylvia
authors.initials: S
authors.lastname: Stadlmann
authors.affiliation: Institute of Pathology, University Hospital Basel, Schönbeinstrasse 40, 4031, Basel, Switzerland.
authors.forename: Luigi
authors.initials: L
authors.lastname: Terracciano
authors.affiliation: Institute of Pathology, Kantonsspital Baden AG, Im Ergel 1, 5404, Baden, Switzerland.|Institute of Pathology, University Hospital Basel, Schönbeinstrasse 40, 4031, Basel, Switzerland.
authors.forename: Gad
authors.initials: G
authors.lastname: Singer
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism; D005260:Female; D006801:Humans; D020381:Interleukin-17 / Q000378:metabolism*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009195:Peroxidase / Q000378:metabolism*; D010984:Platinum / Q000008:administration & dosage* / Q000627:therapeutic use; D012044:Regression Analysis; D016019:Survival Analysis; D046888:Tissue Array Analysis / Q000379:methods; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D020381:Interleukin-17; D010984:Platinum; D009195:Peroxidase
keywords: Chemosensitivity; Interleukin-17; Myeloperoxidase; Ovarian cancer; Synergistic effect